Evidence map›Paper›PMID 40909644›Full record

ArticlebioRxiv : the preprint server for biology2025

Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22.

Kevin C Robertson, Sascha J Amann, Tongkun Liu, Adam V Funk, Xianxi Wang, Irina Grishkovskaya, John R Tabor, Jacqueline L Norris-Drouin, Cheryl H Arrowsmith, Jon L Collins and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Kevin C RobertsonDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA.
Sascha J AmannResearch Institute of Molecular Pathology (IMP), ViennaBioCenter (VBC), Campus-Vienna-Biocenter 1, 1030, Vienna, Austria.
Tongkun LiuCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Adam V FunkCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Xianxi WangDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA.
Irina GrishkovskayaResearch Institute of Molecular Pathology (IMP), ViennaBioCenter (VBC), Campus-Vienna-Biocenter 1, 1030, Vienna, Austria.
John R TaborCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jacqueline L Norris-DrouinCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Cheryl H ArrowsmithStructural Genomics Consortium, University of Toronto, and Princess Margaret Cancer Centre, Toronto, ON, Canada.
Jon L CollinsOffice of the Vice Chancellor for Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Michael J EmanueleDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA.
David HaselbachResearch Institute of Molecular Pathology (IMP), ViennaBioCenter (VBC), Campus-Vienna-Biocenter 1, 1030, Vienna, Austria.
Lindsey I JamesLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
Nicholas G BrownDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA.

Funding

Spindle Assembly Checkpoint SilencingR35GM128855 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nicholas Gene Brown · 2018 to 2026
$4.1M
Proteostasis signaling in cell cycle controlR35GM153250 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael James Emanuele · 2024 to 2026
$1.9M
DISCOVERY OF FIRST-IN-CLASS NSD2 DEGRADERS FOR CANCER THERAPYR01CA242305 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JAMES, LINDSEY INGERMAN · 2019 to 2024
$1.7M
Request for a 500 MHz NMR console and nitrogen-cooled cryoprobeS10OD032476 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEE, ANDREW L · 2022 to 2022
$599k
NCI NIH HHS R01 CA242305NIGMS NIH HHS R35 GM128855NIGMS NIH HHS R35 GM153250NIH HHS S10 OD032476
6 · The paper itself

Abstract

Targeted protein degradation (TPD) through the ubiquitin-proteasome system is driven by compound-mediated polyubiquitination of a protein-of-interest by an E3 ubiquitin (Ub) ligase. To date, relatively few E3s have been successfully utilized for TPD and the governing principles of functional ternary complex formation between the E3, degrader, and protein target remain elusive. FBXO22 has recently been harnessed by several groups to target different proteins for degradation. FBXO22 recruitment has been enabled through degraders that covalently modify its cysteine residues. Here, we reveal that the aldehyde derivative of UNC10088 promotes cooperative binding of FBXO22 to NSD2, a histone methyltransferase and oncogenic protein, leading to a cryo-EM structure of the full SKP1-CUL1-F-box (SCF)-FBXO22 complex with NSD2. This structure revealed a conformational change in the FBXO22 loop surrounding C326, further exposing the cysteine for covalent recruitment. Additional medicinal chemistry efforts led to the discovery of benzaldehyde-based non-prodrug degraders that similarly engage C326 of FBXO22 and potently degrade NSD2. Furthermore, unlike many degraders, our molecules recruit NSD2 to a different surface of FBXO22 than the known FBXO22 substrate BACH1, allowing for concurrent complex formation and degradation of both the neosubstrate and endogenous substrates. Overall, we demonstrate the biochemical and structural basis for NSD2 degradation, revealing key principles for efficient and selective TPD by SCF

Indexed as

cullin-RING ligaseNuclear receptor-binding SET domain-containing 2 (NSD2)SKP1–CUL1–F-box (SCF)Targeted protein degradationUbiquitin Ligase

Identifiers

PMID40909644
PMCPMC12407915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.